PT-141 (Bremelanotide) Medicare Part D Coverage: What's Actually Covered in 2026

Why Medicare Part D Excludes PT-141

Medicare Part D plans are not required to cover drugs used for sexual dysfunction or anorexia when classified as lifestyle agents. PT-141 (bremelanotide) falls squarely into this exclusion category. The Social Security Act §1860D-2(e)(2)(A) lists agents for sexual dysfunction among drug classes that Part D sponsors may exclude from formularies, and virtually all do.

This exclusion is not unique to bremelanotide. Flibanserin (Addyi), the only other FDA-approved HSDD treatment, faces the same Part D restriction. The Centers for Medicare & Medicaid Services (CMS) has maintained this carve-out since Part D's inception in 2006, mirroring the original Medicaid exclusion for erectile dysfunction drugs established by the Deficit Reduction Act of 2005. Unlike drugs for conditions such as diabetes or hypertension, sexual health medications do not qualify for the "protected class" formulary mandates that guarantee Part D inclusion [1].

Some Medicare Advantage (Part C) plans with supplemental drug benefits have historically offered limited coverage of select sexual health medications. But in practice, bremelanotide remains absent from these formularies as well. The drug's high per-dose cost and its narrow FDA indication (premenopausal women only, a demographic that represents a small fraction of Medicare enrollees) make insurer adoption unlikely in the near term.

Beneficiaries who check their plan's formulary on Medicare.gov will find no listing for Vyleesi under any tier.

What PT-141 Costs Without Insurance

The out-of-pocket reality is steep for the brand product. A single Vyleesi autoinjector delivers one 1.75 mg dose, and eight doses (the monthly FDA maximum) carry a retail cost near $1,200 at most chain pharmacies. That figure has remained stable since launch because bremelanotide has no generic equivalent and limited formulary pressure to drive rebates.

Pharmacy benefit managers negotiate rebates on drugs they actually cover. Since most commercial and government plans exclude Vyleesi, AMAG Pharmaceuticals has minimal use to discount the brand product through traditional channels [2].

GoodRx and similar discount aggregators occasionally reduce brand Vyleesi to around $900 to $1,000, but the savings are inconsistent across pharmacy locations. Cash-pay patients purchasing directly from specialty pharmacies report prices between $950 and $1,250 depending on geography and whether they buy in single-dose or four-dose cartons.

The math changes dramatically with compounded bremelanotide. 503B outsourcing facilities compound the active ingredient into subcutaneous vials at roughly $140 per month. That price assumes a standard dosing regimen of 1.75 mg administered as needed, typically 4 to 8 times monthly. The compounded version requires manual syringe preparation rather than an autoinjector, but the pharmacokinetics are equivalent when the same dose reaches subcutaneous tissue [3].

Compounded Bremelanotide: The Most Common Access Route

For Medicare beneficiaries priced out of brand Vyleesi, compounding pharmacies represent the primary access pathway. Section 503B of the Federal Food, Drug, and Cosmetic Act permits outsourcing facilities to compound drugs that are commercially available, provided they meet current good manufacturing practice (cGMP) requirements set by the FDA [4].

Compounded bremelanotide typically comes as a lyophilized powder or a pre-mixed subcutaneous solution in multi-dose vials. Patients draw individual doses using insulin syringes. The process requires basic injection training, which most telehealth providers include during onboarding consultations.

Pricing at 503B facilities ranges from $100 to $180 per month depending on dose count and concentration. Some telehealth platforms that specialize in sexual health bundle the medication cost with monthly provider visits, pushing all-in prices to $160 to $250. That is still 80% to 85% less than brand Vyleesi.

A few considerations when choosing a compounding pharmacy: verify the facility holds FDA 503B registration (searchable on the FDA's registered outsourcing facility list), confirm they perform third-party potency testing on each batch, and ensure the prescribing provider monitors your blood pressure before initiating therapy. Bremelanotide transiently raises systolic blood pressure by an average of 6 mmHg, and the FDA label requires cardiovascular risk assessment before prescribing [5].

The Manufacturer Savings Program and Its Medicare Limitation

AMAG Pharmaceuticals offers the Vyleesi Savings Program for commercially insured patients, reducing copays to as low as $0 for eligible fills. The program is structured as a copay card, and here is the catch: federal law (the Anti-Kickback Statute) prohibits manufacturer copay assistance for patients enrolled in Medicare, Medicaid, TRICARE, or any other federal healthcare program [6].

This means Medicare Part D beneficiaries cannot use the Vyleesi copay card. Period. The restriction applies even if the patient is paying entirely out of pocket and not submitting a claim to Medicare. Enrollment in any federal program disqualifies participation.

For non-Medicare patients with commercial insurance that does cover Vyleesi (a rare scenario), the savings card reduces cost-sharing to $0 to $50 per fill on most plans. But since very few commercial formularies list the drug, the practical value of this program is limited even outside the Medicare population.

Patients sometimes confuse manufacturer copay cards with patient assistance programs (PAPs). PAPs provide free medication to uninsured or underinsured patients who meet income thresholds. As of 2026, AMAG has not established a formal PAP for Vyleesi, though income-qualified patients can inquire directly through the company's patient services line.

Will Medicare Ever Cover Bremelanotide?

Legislative momentum exists, but progress is slow. The Access to Reproductive Healthcare Act and related proposals introduced in recent congressional sessions have sought to remove the Part D exclusion for sexual health medications. None have advanced past committee. The Congressional Budget Office scored one 2023 version and estimated coverage would add approximately $2.1 billion to Part D spending over ten years, a figure that generated bipartisan resistance [7].

From a regulatory perspective, CMS could theoretically issue guidance reinterpreting the lifestyle drug exclusion, but the agency has not signaled intent to do so. The exclusion language in the statute is explicit, and changing it requires congressional action rather than administrative rulemaking.

Dr. Sharon Parish, Professor of Medicine in Clinical Psychiatry at Weill Cornell Medicine and past president of the International Society for the Study of Women's Sexual Health (ISSWSH), has stated: "The exclusion of FDA-approved HSDD treatments from Medicare formularies creates a two-tiered system where sexual health is treated as optional rather than medical. HSDD meets every clinical definition of a disease, and its treatments should be covered accordingly" [8].

A more plausible near-term path involves Medicare Advantage plans adding bremelanotide as a supplemental benefit. MA plans have wide latitude to offer benefits beyond traditional Medicare, and as the MA-enrolled population grows (now exceeding 54% of all Medicare beneficiaries per KFF data), competitive pressure may push some plans to differentiate through sexual health coverage [9].

Clinical Evidence Behind PT-141: What the Trials Showed

Bremelanotide earned FDA approval based on two Phase 3 trials (RECONNECT 1 and RECONNECT 2) enrolling a combined 1,247 premenopausal women with generalized acquired HSDD. In RECONNECT 1 (N=634), patients randomized to bremelanotide 1.75 mg subcutaneous as needed reported a statistically significant increase in desire score on the Female Sexual Function Index (FSFI) desire domain compared to placebo (0.5-point difference, P<0.01). The co-primary endpoint, reduction in distress measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13, also showed significant improvement (difference of -0.4, P<0.006) [10].

These effect sizes are modest. They're also consistent with the only other approved HSDD drug, flibanserin, which showed a 0.3 to 0.4 increase in satisfying sexual events per month over placebo in the VIOLET, DAISY, and BEGONIA trials [11].

The most common adverse event was nausea, affecting 40% of bremelanotide patients versus 1% on placebo. Nausea was most pronounced after the first dose and diminished with repeated use. About 8% of patients discontinued because of it. Focal hyperpigmentation, particularly on the face and gums, occurred in 1% of patients and is believed related to melanocortin-1 receptor activation [10].

Dr. Anita Clayton, Chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia and principal investigator on the RECONNECT program, noted: "The on-demand dosing model of bremelanotide offers a pharmacologic profile distinct from daily flibanserin. For patients who prefer event-driven therapy, this represents a meaningful option" [12].

Bremelanotide acts as a melanocortin-4 receptor (MC4R) agonist in the central nervous system. Unlike PDE5 inhibitors used for erectile dysfunction, it targets desire pathways rather than arousal mechanics. This mechanism means it does not affect genital blood flow directly and is not comparable to sildenafil or tadalafil in pharmacologic action [3].

Alternative Coverage and Discount Strategies

Medicare beneficiaries seeking affordable access to bremelanotide have several concrete options beyond full cash pay for brand Vyleesi.

Compounded bremelanotide through telehealth. This is the most cost-effective route. Prices range from $100 to $180 monthly. Ensure the pharmacy is FDA-registered under Section 503B. HealthRX and similar platforms connect patients with licensed providers who can prescribe compounded formulations after a clinical evaluation.

State Pharmaceutical Assistance Programs (SPAPs). Some states operate SPAPs that supplement Medicare Part D coverage. While most exclude lifestyle medications, a few states (notably New York and New Jersey) have broader formularies. Check your state's SPAP through the Medicare.gov SPAP finder [13].

Nonprofit patient assistance. Organizations like NeedyMeds and RxAssist maintain databases of manufacturer and independent assistance programs. While no dedicated Vyleesi PAP exists as of 2026, eligibility for broader women's health assistance funds may apply depending on income [14].

Medigap supplemental policies. Medigap plans (Medicare Supplement Insurance) cover cost-sharing for Part A and Part B services. They do not extend to Part D drug costs and will not help with bremelanotide. This is a common misconception worth clarifying.

Health Savings Accounts and Flexible Spending Accounts. Medicare beneficiaries enrolled before establishing an HSA can use remaining HSA funds to pay for bremelanotide out of pocket. FSAs are not available to Medicare enrollees. IRS Publication 502 confirms that prescription drugs are qualified medical expenses for HSA distributions regardless of insurance coverage status [15].

Off-Label Considerations and the Male Use Question

Bremelanotide's FDA indication is limited to premenopausal women with acquired, generalized HSDD. It is not approved for postmenopausal women, men, or any non-HSDD indication. The RECONNECT trials excluded postmenopausal women, so no Phase 3 efficacy data exists for this population.

Despite the narrow label, off-label prescribing of bremelanotide occurs in clinical practice. Some providers prescribe it to postmenopausal women with HSDD, extrapolating from the premenopausal data and from Phase 2 data in a mixed-age cohort that included postmenopausal subjects. A small Phase 2b study (N=327) did include postmenopausal women and showed a trend toward benefit, but the study was not powered for a subgroup analysis by menopausal status [10].

Male use of bremelanotide (often referenced as "PT-141" in the peptide therapy community) has been explored in early-phase studies for erectile dysfunction. A Phase 2 study of intranasal bremelanotide in men with ED (N=342) showed improvement in erectile function versus placebo, but the intranasal formulation was abandoned due to blood pressure concerns [16]. The subcutaneous formulation has not been studied in a Phase 3 male ED trial. Any male use is off-label and unsupported by registration-quality evidence.

Medicare Part D would not cover off-label use even if the drug were on formulary, unless the use is supported by a CMS-recognized compendium citation. No such citation exists for bremelanotide in men or postmenopausal women.

Blood Pressure Monitoring and Safety Precautions

Bremelanotide causes a transient, dose-dependent increase in blood pressure. In the RECONNECT trials, mean systolic blood pressure rose by 6 mmHg and diastolic by 3 mmHg within 2 to 3 hours of dosing, returning to baseline by 12 hours [5]. The FDA label contraindicates bremelanotide in patients with uncontrolled hypertension or known cardiovascular disease due to this effect.

Before initiating therapy, providers should confirm resting blood pressure is below 140/90 mmHg. Patients taking antihypertensive medications may use bremelanotide, but blood pressure should be monitored more frequently during the first month. Concomitant use with naltrexone is specifically warned against because bremelanotide decreased the systemic exposure of naltrexone by approximately 40% in a pharmacokinetic interaction study, potentially reducing naltrexone's efficacy for alcohol or opioid use disorder treatment [5].

Patients should not use more than one dose in a 24-hour period and no more than 8 doses per calendar month. The FDA's dosing ceiling exists because long-term cardiovascular effects of frequent MC4R agonist exposure have not been fully characterized beyond the 12-month open-label extension data from RECONNECT [10].